Skip to main content

Table 1 Clinical features of patients in training cohort and test cohort

From: Deep-learning-based radiomics of intratumoral and peritumoral MRI images to predict the pathological features of adjuvant radiotherapy in early-stage cervical squamous cell carcinoma

Variable

All cohort

Training cohort

Test cohort

P-value*

P-value**

no AR (n = 101)

AR(n = 130)

P

no AR (n = 25)

AR (n = 33)

P-value

Age(year)***

49.30 ± 10.16

48.64 ± 11.14

50.58 ± 9.38

0.10

45.52 ± 8.56

49.12 ± 10.59

0.15

0.13

0.03

parametrial invasion-clinical palpation

   

0.15

  

1.00

1.00

0.14

No ( n, % )

272 (94.12)

98(97.03)

119(91.54)

 

24(96.00)

31(93.94)

   

Yes ( n,% )

17 (5.88)

3(2.97)

11(8.46)

 

1(4.00)

2(6.06)

   

MTD-MRI(cm)

3.24 ± 1.41

2.85 ± 1.34

3.45 ± 1.33

< 0.001

2.84 ± 1.42

3.88 ± 1.53

0.02

0.21

< 0.001

vagina-positive MRI

   

0.79

  

0.53

0.76

1.00

No ( n,% )

177 (61.25)

64(63.37)

79(60.77)

 

13(52.00)

21(63.64)

   

Yes ( n,% )

112 (38.75)

37(36.63)

51(39.23)

 

12(48.00)

12(36.36)

   

Lymph node-positive MRI

   

0.01

  

0.13

0.44

< 0.001

No ( n,% )

246 (85.12)

94(93.07)

105(80.77)

 

23(92.00)

24(72.73)

   

Yes ( n,% )

43 (14.88)

7(6.93)

25(19.23)

 

2(8.00)

9(27.27)

   

MRI scanner

   

0.78

  

1.00

0.56

0.79

3.0 T ( n,% )

93(32.18)

30(29.70)

42(32.31)

 

9(36.00)

12(36.36)

   

1.5 T ( n,% )

196(67.82)

71(70.30)

88(67.69)

 

16(64.00)

21(63.64)

   

White blood cell(×109/L)***

9.94 ± 3.46

9.96 ± 3.40

10.08 ± 3.05

0.57

10.05 ± 3.88

9.23 ± 4.68

0.49

0.63

0.92

Neurtophil(×109/L)***

8.01 ± 3.41

7.99 ± 3.49

8.07 ± 3.06

0.63

8.27 ± 3.80

7.68 ± 4.20

0.56

0.87

0.89

Lymphocyte(×109/L)***

1.31 ± 0.56

1.32 ± 0.59

1.37 ± 0.59

0.55

1.21 ± 0.44

1.15 ± 0.34

0.48

0.10

0.77

Erythrocytes(×1012/L)***

3.69 ± 0.66

3.77 ± 0.59

3.75 ± 0.59

0.73

3.52 ± 0.65

3.29 ± 0.93

0.15

< 0.001

0.41

Hemoglobin(G/L)***

104.68 ± 18.45

106.55 ± 16.71

105.32 ± 17.08

0.44

105.72 ± 11.45

95.64 ± 28.61

0.09

0.23

0.17

Thrombocyte(×109/L)***

220.58 ± 70.43

217.62 ± 62.25

233.42 ± 72.41

0.11

202.28 ± 60.00

192.97 ± 83.40

0.77

0.05

0.21

ALP(U/L)***

53.76 ± 39.09

49.97 ± 39.92

59.08 ± 39.32

0.11

49.96 ± 31.81

47.33 ± 39.60

0.9

0.21

0.15

LDH(U/L)***

121.56 ± 82.38

113.15 ± 85.56

130.84 ± 79.93

0.12

125.62 ± 76.71

107.67 ± 85.11

0.59

0.59

0.26

ALb(G/L)***

28.14 ± 17.78

26.69 ± 18.91

29.57 ± 16.66

0.86

30.41 ± 17.16

25.23 ± 18.97

0.37

0.78

0.80

Creatinine(mmol/L)***

30.62 ± 29.57

25.49 ± 29.13

35.27 ± 29.68

0.03

37.32 ± 28.54

22.95 ± 28.06

0.07

0.72

0.23

SCC-Ag(ng/mL)***

3.45 ± 6.51

1.86 ± 2.41

4.86 ± 8.67

< 0.001

2.10 ± 1.96

3.82 ± 6.30

0.92

0.47

< 0.001

Mononuclear cell(×109/L)***

0.52 ± 0.28

0.52 ± 0.22

0.52 ± 0.34

0.27

0.50 ± 0.19

0.54 ± 0.27

0.97

0.73

0.30

LMR***

2.96 ± 1.71

2.84 ± 1.39

3.20 ± 2.03

0.42

2.75 ± 1.42

2.58 ± 1.31

0.63

0.21

0.62

LNR***

0.23 ± 0.20

0.22 ± 0.19

0.22 ± 0.19

0.89

0.22 ± 0.22

0.26 ± 0.27

0.73

0.88

0.80

  1. AR: adjuvant radiotherapy; MTD-MRI:maximal tumor diameter on MR images of the largest lesions; ALP: alkaline phosphatase; LDH: lactate dehydrogenase ALb: albumin; SCC-Ag: squamous cell carcinoma antigen; LMR: lymphocyte/monocyte ratio; LNR: lymphocyte/neutrophil ratio;P-value*: the difference of each clinical variable between the training and test cohorts; P-value**: the difference of each clinical variable between no adjuvant radiotherapy group and adjuvant radiotherapy group. P < 0.05 indicates statistically significant. ***: mean, standard deviation.